Dassault Systèmes (DSY) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
9 Feb, 2026Executive summary
Q2 2024 revenue rose 4% year-over-year to €1.50 billion, with non-IFRS diluted EPS up 8% to €0.30; H1 2024 revenue grew 5% to €3.00 billion, and non-IFRS EPS increased 10% to €0.60.
Recurring software revenue represented 82% of software revenue in H1, with subscription revenue up 9% and strong cloud and 3DEXPERIENCE momentum.
Operating margin (non-IFRS) was 29.9% in Q2 and 30.5% in H1; IFRS operating margin improved to 20.0%.
Growth was driven by robust demand for 3DEXPERIENCE and cloud solutions, with notable wins in manufacturing, life sciences, and infrastructure.
Customer decision delays and volatility impacted Q2 and late June, but a strong pipeline is expected to drive a robust H2.
Financial highlights
Q2 software revenue up 3%, subscription revenue up 8–9%, and upfront license revenue down 1%.
H1 software revenue reached €2.70 billion (+5%), with Industrial Innovation up 6%, Mainstream Innovation up 9%, and Life Sciences down 2%.
Operating cash flow for H1 was €1.13 billion, up 10% year-over-year; cash and cash equivalents at €4.03 billion, net financial position at €1.04 billion.
Non-IFRS net income for H1 was €794 million (+7%); IFRS net income was €548 million (+15%).
Q2 closing headcount was 25,811, up 3% year-over-year.
Outlook and guidance
Full-year 2024 non-IFRS revenue guidance: €6.26–€6.335 billion (6–8% growth); software revenue expected to grow 7–8%, recurring revenue 8–9%, subscription revenue 13–15%.
Non-IFRS operating margin forecasted at 32–32.4%; diluted EPS expected at €1.27–€1.30 (8–11% growth).
Q3 2024 non-IFRS revenue guidance: €1.466–€1.506 billion, with EPS of €0.28–€0.29.
H2 revenue growth expected at 9% sequentially, with two-thirds from seasonality and one-third from delayed deals and back-end loaded contracts.
Guidance assumes US$/€1.09 and JPY/€159.7 for FY 2024.
Latest events from Dassault Systèmes
- Q2 revenue and EPS rose, cloud and AI advanced, ArisGlobal boosts Life Sciences growth.DSY
Q2 202625 Jul 2026 - Revenue and EPS rose, margins expanded, and Life Sciences strengthened by ArisGlobal acquisition.DSY
Q2 2026 Investor call23 Jul 2026 - Q3 revenue up 4% to €1.46B; FY EPS guidance reaffirmed, with Q4 growth acceleration expected.DSY
Q3 20249 Jul 2026 - FY25 revenue rose 4% to €6,240M, with ARR at €4.5B and FY26 growth targeted at 3–5%.DSY
Q4 2025 Investor Call9 Jul 2026 - Pascal Daloz takes over as Chairman and CEO as the company advances its Industrial AI strategy.DSY
Investor update8 Jul 2026 - Q1 2026 saw 3% revenue growth, strong cash flow, and confirmed full-year guidance.DSY
Q1 2026 Investor Call23 Apr 2026 - Q1 2026 saw 3% revenue growth, strong cash flow, and confirmed outlook with robust AI and cloud momentum.DSY
Q1 202623 Apr 2026 - FY26 targets 3–5% revenue growth, margin expansion, and strong ARR momentum.DSY
Q4 202511 Feb 2026 - Q2 revenue up 6%, guidance reaffirmed, strong 3DEXPERIENCE and cloud growth.DSY
Q2 20259 Feb 2026